摘要
目的:观察达格列净在非糖尿病合并慢性心力衰竭(CHF)患者治疗中的应用效果。方法:选取2022年1—6月巨野县人民医院心血管内科收治的120例非糖尿病合并CHF患者,随机分为对照组和达格列净组各60例。对照组患者给予限盐、利尿、β-受体阻断药、沙库巴曲缬沙坦钠片等心衰药物治疗,达格列净组患者在对照组治疗基础上给予达格列净10 mg口服,对所有入选患者随访半年。记录两组患者入院时及治疗6个月后空腹血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c),氨基末端脑钠肽前体(NT-proBNP)、6 min步行距离(6-MWD),心脏超声指标情况;包括左心房内径(LAD)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD),记录并比较两组患者不良药物事件和主要心脏不良事件(MACE)发生率。结果:治疗6个月后,达格列净组患者NTproBNP、LAD、LVESD低于对照组患者,6-MWD、LVEF高于对照组患者,差异有统计学意义(P<0.05)。治疗6个月后,两组患者主要药物不良反应事件总发生率比较,差异无统计学意义(P>0.05);达格列净组患者MACE发生率低于对照组患者,差异有统计学意义(P<0.05)。结论:达格列净能有效抑制非糖尿病合并CHF患者心室重构,提高患者心功能,改善患者预后,同时具有良好的安全性。
Objective To investigate the effect of Dapagliflozin in the treatment of non-diabetic patients with chronic heart failure(CHF).Methods A total of 120 non-diabetic patients with CHF treated in the cardiovascular Department of Juye County People's Hospital from January to June 2022 were randomly divided into control group and Dapagliflozin group with 60 cases in each group.Control group was treated with heart failure drugs such as salt-limiting,diuretic,beta-receptor blocking drug and Sacubitril Valsartan Sodium Tablets,while Dapagliflozin group was given 10 mg of Dapagliflozin orally on the basis of control group.All enrolled patients were followed up for six months.Fasting blood glucose(FBG),2 h postprandial blood glucose(2 hPG),glycated hemoglobin(HbA1c),N-terminal pro-brain natriuretic peptide(NT-proBNP),6-min walking distance(6-MWD)and cardiac ultrasound indexes of the two groups were recorded at admission and 6 months after treatment.Left atrial diameter(LAD),left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)were included.Adverse drug events and the incidence of major cardiac adverse events(MACE)were recorded and compared between the two groups.Results After 6 months of treatment,NT-proBNP,LAD and LVESD in Dapagliflozin group were lower than those in control group,and 6-MWD and LVEF were higher than those in control group,with statistical significance(P<0.05).After 6 months of treatment,there was no significant difference in major adverse drug reaction events between the two groups(P>0.05).The incidence of MACE in Dapagliflozin group was lower than that in control group,and the difference was statistically significant(P<0.05).Conclusions Dapagliflozin can effectively inhibit and improve ventricular remodeling in non-diabetic patients with CHF patients with cardiac function,improve patient prognosis,and have good safety.
作者
郎燕
吕淑珍
LANG Yan;LYU Shuzhen(The Second Department of Cardiology,Juye County People’s Hospital,Heze,Shandong 274900,China;The Third Department of Neurology,Juye County People’s Hospital,Heze,Shandong 274900,China)
出处
《医药前沿》
2023年第17期4-6,共3页
Journal of Frontiers of Medicine
关键词
达格列净
慢性心力衰竭
糖尿病
心功能
预后
Dapagliflozin
Chronic heart failure
Diabetes
Cardiac function
Prognosis
